Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bradenton, FL
NPI
1659699072
Since 2010
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
11715 Rangeland Pkwy
Bradenton, FL, 34211
Phone (941) 538-0077
Groups this clinician bills Medicare through
Medicare paid, 2024
$736K
59,319 services
Medicare patients, 2024
1,569
Average age 75
Drug cost, 2024
$3.2M
3,980 prescriptions
Company payments, 2025
$522
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Deborah Majchel Koss was code J3111 (injection, romosozumab-aqqg, 1 mg), 37,800 times for 30 patients. In total Deborah Majchel Koss billed 59,319 services in 60 codes, and Medicare paid $736K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 37,800 | 30 | $8.54 | $323K |
| J0897 Injection, denosumab, 1 mg | Office | 6,840 | 79 | $20.43 | $140K |
| 99214 Office E&M - Established | Office | 1,143 | 542 | $90.12 | $103K |
| 77080 Standard X-ray | Office | 807 | 807 | $36.56 | $30K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 770 | 503 | $12.42 | $9,566 |
| 36415 Venipuncture Blood Collection | Office | 754 | 432 | $8.64 | $6,514 |
| 95251 Test - Miscellaneous | Office | 531 | 215 | $25.13 | $13K |
| 77089 Standard X-ray | Office | 475 | 475 | $29.55 | $14K |
| 83036 Blood Count | Office | 413 | 224 | $9.52 | $3,932 |
| 96401 Chemotherapy Administration | Office | 295 | 102 | $53.41 | $16K |
| 84443 Clinical Chemistry | Office | 231 | 157 | $16.46 | $3,802 |
| 80053 Clinical Chemistry | Office | 217 | 194 | $10.35 | $2,246 |
| 99213 Office E&M - Established | Office | 184 | 170 | $64.06 | $12K |
| 82306 Clinical Chemistry | Office | 182 | 159 | $29.01 | $5,280 |
| 82043 Clinical Chemistry | Office | 144 | 120 | $5.66 | $815 |
By year: 2022 $574K for 51,751 services; 2023 $542K for 45,884 services; 2024 $736K for 59,319 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 754 | 432 | $8.64 | $6,514 |
| 83036 Blood Count | 413 | 224 | $9.52 | $3,932 |
| 84443 Clinical Chemistry | 231 | 157 | $16.46 | $3,802 |
| 80053 Clinical Chemistry | 217 | 194 | $10.35 | $2,246 |
| 82306 Clinical Chemistry | 182 | 159 | $29.01 | $5,280 |
| 82043 Clinical Chemistry | 144 | 120 | $5.66 | $815 |
| 82570 Clinical Chemistry | 144 | 120 | $5.08 | $732 |
| 80048 Clinical Chemistry | 137 | 111 | $8.29 | $1,136 |
| 82607 Clinical Chemistry | 106 | 102 | $14.78 | $1,567 |
| 82565 Clinical Chemistry | 87 | 71 | $5.02 | $437 |
Medicare prescription drug claims, 2024
In 2024, the drug Deborah Majchel Koss prescribed most often to Medicare patients was Ozempic (Semaglutide), with 377 prescriptions and refills. In total Deborah Majchel Koss wrote 3,980 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 377 | 712 | 97 | $681K |
| Levothyroxine Sodium Generic | 338 | 973 | 97 | $3,404 |
| Mounjaro Tirzepatide | 314 | 444 | 70 | $465K |
| Metformin Hcl Er Metformin Hcl | 291 | 870 | 110 | $2,350 |
| Metformin Hcl Generic | 179 | 521 | 58 | $1,303 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 165 | 494 | 72 | $13K |
| Glipizide Er Glipizide | 148 | 440 | 61 | $1,899 |
| Jardiance Empagliflozin | 138 | 322 | 42 | $185K |
| Trulicity Dulaglutide | 137 | 241 | 35 | $230K |
| Tresiba Flextouch U-200 Insulin Degludec | 135 | 332 | 47 | $249K |
| Alendronate Sodium Generic | 128 | 353 | 44 | $985 |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 115 | 252 | 38 | $208K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 86 | 188 | 20 | $124K |
| Xultophy 100-3.6 Insulin Degludec/Liraglutide | 77 | 180 | 39 | $207K |
| Glimepiride Generic | 68 | 204 | 24 | $809 |
Brand drugs: 2,170 claims; generic drugs: 1,451 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Deborah Majchel Koss $522 ($522 in general payments such as food, travel and fees) from 12 companies. The largest payer was Sequel Med Tech, LLC with $151.
| Company | Payments | Amount |
|---|---|---|
| Sequel Med Tech, LLC | 2 | $151 |
| Corcept Therapeutics CORT | 6 | $146 |
| Amgen Inc. AMGN | 3 | $66.72 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $25.34 |
| Recordati_rare_diseases_inc. | 1 | $22.16 |
| Madrigal Pharmaceuticals MDGL | 1 | $19.89 |
| Novo Nordisk Inc NVO | 1 | $19.4 |
| Boston Scientific Corporation BSX | 1 | $17.44 |
| Tandem Diabetes Care, Inc. TNDM | 1 | $16.68 |
| Aimmune Therapeutics, Inc. | 1 | $15.3 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.